Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease [PDF]
, 2005 Sotiria C. Apostolopoulou
openalex +1 more source
"Survival with first-line bosentan in patients with primary pulmonary hypertension". V. V. McLaughlin, O. Sitbon, D. B. Badesch, R. J. Barst, C. Black, N. Galie, M. Rainisio, G. Simonneau, and L. J. Rubin. Eur Respir J 2005; 25: 244-249. [PDF]
, 2005 openalex +1 more source
Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
Annals of Pediatric Cardiology, 2009 We report the use of Bosentan in the post-operative period of a neonate with obstructed infradiaphragmatic total anomalous pulmonary venous connection and severe pulmonary arterial hypertension.
Pawar Ravindra +3 more
doaj
RESPONSE OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION THAT DO NOT QUALIFY FOR TREATMENT WITH BOSENTAN TO TREATMENT WITH BOSENTAN [PDF]
, 2005 Zoheir Bshouty
openalex +1 more source
CASE REPORT: BOSENTAN-RESISTANT SARCOIDOSIS-ASSOCIATED PULMONARY HYPERTENSION RESPONSIVE TO SILDENAFIL [PDF]
, 2005 Haroon Faraz +4 more
openalex +1 more source
Therapeutic Advances in Respiratory DiseaseBackground: Liver injury is the hallmark adverse reaction of endothelin receptor antagonist (ERA). Since the first drug, bosentan has been widely used in clinical practice, hepatotoxicity has been accompanied by the history of ERA.
Shichao Dong +3 more
doaj +1 more source
Efficacy of Bosentan in a Small Cohort of Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease [PDF]
, 2006 Raymond L. Benza +6 more
openalex +1 more source